Genomics and New Medicine Discovery
We deliver actionable policy to support these evolving sectors in the UK and offer broader policy insights into related areas of global focus
Why is this important?
New treatments such as cell and gene therapy hold immense promise and will increasingly inform strategies for addressing global public health threats, both in the short and long-term. However, governments and system leaders must work to ensure that the transformational benefits of genomics and new medicines are felt equally across the world.
What we do
We deliver actionable policy to support these evolving sectors in the UK and offer broader policy insights into related areas of global focus.
What are the benefits?
Recent years have witnessed rapid advances in the treatment of infectious and rare diseases, and genomic science lays at the heart of much of this progress.
Sharing these advances fairly will help to create a more resilient and equal world, ensuring that genomics-based healthcare interventions can be accessed by all, for the benefit of all.
Equity of Access and Return in Global Genomics
Implementing precision medicine in the UK: The case of cancer vaccines
Personalised neoantigen cancer vaccines potentially represent the next paradigm shift in precision treatment for cancer patients. Given that research into cancer vaccines is at an early stage, the UK is well-placed to utilise its competitive advantage to attract investment. This includes the experience of running some of the fastest recruiting pandemic vaccines studies, its outstanding genomic capabilities and research talent and experience.